NCT06850103View on ClinicalTrials.gov

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2032

Conditions
Colorectal CarcinomaOligometastasespMMRMSSiTNT
Interventions
RADIATION

short-course radiotherapy

Neoadjuvant short-course radiotherapy (SCRT) will be administered at a total dose of 25 Gy, delivered in 5 fractions of 5 Gy each.

DRUG

CAPEOX/XELOX

Capecitabine: 1000 mg/m² BID, D1-14, Q3W × 4 cycles Oxaliplatin: 130 mg/m² IV, D1, Q3W × 4 cycles

DRUG

Serplulimab

Serplulimab: 300 mg IV, D1, Q3W × 4 cycles

PROCEDURE

surgery

Primary tumor: Total Mesorectal Excision (TME) Metastatic lesions: Local therapeutic intervention

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER